1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Competitive Grants Program (Research) is sponsored by Pfizer. Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.
Autoimmune oophoritis and POI represent areas of unmet medical need, making this a potential fit if an RFP aligns with the specific research.
Get alerted about grants like this
Save a search for “Pfizer” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Competitive Grants Program | Pfizer Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.
The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Shared Decision Making in Hemophilia Patient Care Release Date: December 11, 2025 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Rare Disease China April 10, 2026 Optimizing HRRm Testing and Workflow Integration in mCSPC Release Date: January 12, 2026 Review Process: Expert Review Panel View RFP (PDF) Quality Improvement, Research Oncology Canada April 8, 2026 Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across Canada Release Date: January 15, 2026 Partner: Colorectal Cancer Canada (CCC) Review Process: Expert Review Panel View RFP (PDF) Quality Improvement, Research Oncology Canada April 15, 2026 Optimizing Disease Management to Improve Alopecia Areata Quality of Care Release Date: January 15, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Inflammation & Immunology China April 30, 2026 Providing Appropriate Medical Care for IBD Patients Release Date: January 27, 2026 Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD) Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Inflammation & Immunology Japan April 19, 2026 Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) Therapy Release Date: February 4, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology Canada April 22, 2026 2026 Headache Medicine Fellowship - US Release Date: February 9, 2026 Review Process: Expert Review Panel View RFP (PDF) Fellowship Internal Medicine USA April 6, 2026 Advances in Migraine Management Release Date: February 11, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Internal Medicine USA May 8, 2026 Optimizing Atopic Dermatitis Quality of Care and Best Practice at Local Level Release Date: February 14, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Inflammation & Immunology China April 30, 2026 Real-World Evidence of SUL-DUR on Special Populations with CRAB Infection Release Date: February 14, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Inflammation & Immunology China April 7, 2026 Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Pneumococcal Disease Prevention Release Date: April 11, 2012 Review Process: View RFP (PDF) Release Date: May 8, 2012 Review Process: View RFP (PDF) Release Date: June 28, 2012 Review Process: View RFP (PDF) Pharmacy Pneumococcal Disease Prevention Release Date: June 28, 2012 Review Process: View RFP (PDF) Release Date: July 2, 2012 Review Process: View RFP (PDF) Non-Small Cell Lung Cancer Release Date: July 10, 2012 Review Process: View RFP (PDF) Cardiovascular Risk in Rheumatoid Arthritis Release Date: July 25, 2012 Review Process: View RFP (PDF) Release Date: July 26, 2012 Review Process: View RFP (PDF) Adult Pneumococcal Disease Prevention Release Date: August 29, 2012 Review Process: View RFP (PDF) Prevention of Stroke in Women Release Date: September 13, 2012 Review Process: View RFP (PDF) Oncology Educational Needs Assessments Release Date: October 22, 2012 Review Process: View RFP (PDF) Release Date: November 1, 2012 Review Process: View RFP (PDF)
Based on current listing details, eligibility includes: Organizations that can address specific gaps in research, practice, or care as outlined in publicly posted Requests for Proposal (RFPs). Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Undisclosed Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.